Management of recurrent or metastatic XXXX in Germany: results of the nationwide AGO pattern of care studies from the years 2013, 2009 and 2006.

@entity1204 @entity1 @entity440 @entity5948 @entity3907 @entity1871 @entity1299 @entity902
PURPOSE: The available literature on the treatment options for recurrent or metastatic @entity1204 ( @entity1204 ) is full of controversies. Therefore, we explore the results of the AGO pattern of care studies from the years 2013, 2009 and 2006. METHODS: A questionnaire was developed and sent to all 682 German gynecological departments in 2013 (775 in 2009, 500 in 2006, respectively). The results of the questionnaires were compared with each other using Fisher's exact test. RESULTS: Responses were available in 40.0  % in 2013, 33.3  % in 2009 and 35.8  % in 2006. In 2013 the most preferred endocrine drug was progestin (79.8  %), followed by @entity440 (42.8  %), aromatase inhibitor (19.8  %), @entity1299 (16.3  %) and a combination (3.9  %) (p  <  0.001). 65.3, 59.8, 51.7 and 38.2  % of the @entity1 used @entity902 , @entity3907 , a combination of cytostatic drugs, @entity5948 in metastatic @entity1204 , respectively (p  =  0.215). 96.2, 92.7, 49.8 and 60.9  % of the @entity1 performed an operation, radiotherapy, endocrine therapy and chemotherapy in 2013 because of a local recurrence, respectively (p  <  0.001). Compared to 2009 and 2006 these rates remained stable (no p value <0.05). Because of a distant metastasis 50.4, 64.2, 78.5 and 90.8  % of the @entity1 performed an operation, radiotherapy, endocrine therapy and chemotherapy in 2013, respectively (p  <  0.001). Compared to 2009 and 2006 more @entity1 performed an operation or radiotherapy and less an endocrine treatment. CONCLUSIONS: Whereas @entity1871 was the favorite drug, the @entity1 of this study did not prefer a specific cytostatic drug for metastatic @entity1204 in 2013. This might have reflected the available literature, which did not provide a real standard of care.
